In addition, activating mutations at Y641 amino acid in the EZH2 gene within the EZH2 catalytic SET domain are recurrently and significantly mutated in up to 40% of B-cell lymphomas [10], and particularly in approximately 13–22% of DLBCL [4,11,12]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.